Theralase Technologies Inc. has seen a slight uptick in its stock performance this week, amidst ongoing financing activities.
Theralase Technologies Inc. (TLT.V) closed on Friday at C$0.18, reflecting a 2.63% decline on the day, but a notable 2.78% increase over the past week. The company continues to navigate its financial landscape with recent funding initiatives aimed at bolstering its clinical development programs.
Advertisement
Theralase Technologies Inc.
TLT.V
TLT.V
Theralase Technologies Inc.
WealthAwesomeMarket cap
$58.99M
52W high
$0.41
52W low
$0.15
1W change
+2.78%
Beta
0.49
Analyst Price Targets
Based on analyst covering TLT
Wall Street analysts forecast TLT stock price to rise 278.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+278.4% Upside
Current Price
C$0.18
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLT's historical volatility
30-Day Vol
88.7%
Annualized
90-Day Vol
90.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.15
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.17 | C$0.13 โ C$0.24 |
| 60 trading days | C$0.16 | C$0.11 โ C$0.25 |
| 90 trading days | C$0.15 | C$0.09 โ C$0.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider Theralase's recent financial activities, including its brokered offerings and stock options grants, as potential indicators of the company's strategic direction and future growth prospects.
C$589,918,32 Market Cap with a 0.0% Profit Margin
Theralase's market capitalization stands at approximately C$58.99 million, but its profit margin remains at 0.0%, indicating challenges in converting revenue into profit.
Bull case
The completion of a C$3.6 million brokered financing and the initiation of a $5 million LIFE offering may provide Theralase with the capital needed to advance its clinical studies and operational goals. This could position the company for future growth.
Bear case
Despite recent fundraising efforts, Theralase's financial metrics, including a negative profit margin and a high return on equity deficit, raise concerns about its long-term sustainability and operational efficiency.
Recent Stock Performance
Advertisement
Theralase Technologies Inc. has seen a 1D decline of 2.63%, closing at C$0.18. However, over the past week, the stock has gained 2.78%. Year-to-date, the stock remains relatively stable, also up 2.78%. The latest trading volume was 19,627 shares, which is notably lower than the 20-day average volume of 397,155 shares.
Recent Company News
Theralase has been active recently, announcing several key financial moves. The company completed a C$3.6 million brokered financing and initiated a $5 million brokered LIFE offering aimed at funding its ongoing clinical studies. Additionally, Theralase granted stock options to directors and officers to align their interests with shareholders. Furthermore, it filed a base shelf prospectus allowing it to raise up to C$100 million over the next 25 months.
Technical Picture
Theralase's stock is currently trading below both its 50-day moving average of C$0.23 and its 200-day moving average of C$0.25, indicating a bearish trend in the short to medium term. The stock has a 52-week range of C$0.15 to C$0.41, currently standing at 13% of that range. With a beta of 0.49, the stock has shown less volatility compared to the broader market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
